In the STEP program, more than half of those treated with a single dose (1.5 mg/day) of the dietary supplement level 1 achieved a weight loss of at least 10% of their body weight compared to placebo. STEP programs resulted in less than one-third of people with overweight or obese BMI gaining less than 1% compared to placebo. Step program and a higher proportion were achieved by treating them with one or more doses of STEP than with the placebo or placebo were given in combination with no diet or exercise. [Sources: 4]

More than half of those treated with a single dose (1.5 mg/day) of the level 1 dietary supplements achieved a weight loss of at least 10% of their body weight compared to placebo. In the STEP program, a higher proportion (29.2% and 28.4%, respectively) was achieved by treating them with one or more doses of STEP than with placebo or placebo, which were not administered in combination with any diet or exercise. Less than one-third (37.3%) or about half (47.6%) of people with an overweight or obese BMI gain 1% (0.7-2.1% compared to placebo, and less than one quarter (25.8 %-26.9%). It achieved less than two-thirds (63.0% / year) or less or about three-quarters (73% / year) of all treated weight loss of less than one-third (-1 / 4 – 3% versus 2 / 5% in the control group, but more than on average 3 / 6 – 7% in obese and overweight individuals). [Sources: 4]

In adults who were overweight or obese, the one- to weekly subcutaneous use of semaglutide resulted in significantly greater weight loss compared to placebo, which was used for 68 weeks. It increased the average weight loss by 10.3 percentage points for those who used intensive behavioral therapy in combination with one or more doses of the level 1 dietary supplement (1.5 mg/day) and exercise (2.0-3.1%). In adults with overweight/obesity: Once a week subcutaneous semen lutides compared to placebo or as part of a simple diet and/or exercise program resulted in weight gain of at least 10% (10-13%). In overweight or obese adults: In adolescents with overweight and obesity, a monthly dose of subcutaneous semen lutides (0.6 mg per day compared to placebo) or a combination of a dose (3-4 mg/day) of the dietary supplement stage 2 (4-6 mg – 7.2 mg), which results in significant weight loss over 68 weeks in adults with overweight and obesity: a daily dose or the intake of once-monthly subcutaneous semen lutide (5-8 mg). [Sources: 3] Semaglutide and diabetes

The study participants were men and women between 18 and 65 years of age with a BMI of at least 25. The study was conducted in adults with concomitant weight-related diseases such as type 1 and type 2 diabetes, hypertension, cardiovascular disease and diabetes mellitus, and obesity. All were enrolled because of their risk of joining the study. And the comorbidity related to her existing condition, which included type 2 diabetes and high blood pressure, and not. [Sources: 8, 10]

Those who were overweight or obese, including those with prediabetes, hypertension, and obstructive sleep apnea, were recommended to have sedentary exercise therapy of at least 30 minutes a day, once or weekly. Those who took part in the study and those who did not take part were also given advice on diet and fitness. [Sources: 0, 12]

Previous results from Phase 2 studies have found a positive association between sedentary exercise therapy and weight loss in adults with obesity, but it has not been confirmed that adult obesity can be achieved by using a once-weekly sedative such as sedation or exercise with weight loss. [Sources: 2, 7]

This double-blind study randomly assigned adults with obesity and diabetes to step up or down in the form of a once-weekly sedative or exercise therapy. The study examined the effect of once-weekly sedation on weight loss compared to placebo in adult obese or diabetic patients with a history of diabetes. [Sources: 5, 9]